Investor · 1 deal
Every published round MPM Capital took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Peplin Inc | Unnamed stage | 18 Aug 2008 | $24m | Participant | GBS Ventures (Mon 18 Aug 2008), GBS Ventures (Mon 18 Aug 2008) |
Companies MPM Capital has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Peplin Inc | 18 Aug 2008 | 1 | 0 |
Fund closes reported for MPM Capital, as distinct from the investments it has made.
Companies MPM Capital has backed that another company then bought. An exit for the holding, not a deal MPM Capital did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| Peplin Inc | LEO Pharma A/S | Acquisition | 3 Sep 2009 | ~$348.4m |
Stories naming MPM Capital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Blade Therapeutics reports its Phase 2 trial of BLD-2660 in COVID-19 pneumonia has enrolled half its 120-patient goal, with full enrollment expected in the third quarter of 2020.
Blade Therapeutics appoints Mark Timney as board chairman, succeeding co-founder Luke Evnin; the release recalls its roughly $90 million raised from investors including OneVentures and The Medicines Company's $9.7 billion sale to Novartis.
Leo Pharma has agreed a US$287.5m cash takeover of Peplin, the ASX-listed skin-disease drug developer in GBS Ventures' portfolio; GBS recalls leading its late-2008 round alongside two American venture backers.
LEO Pharma has struck a deal to buy ASX-listed Peplin for roughly US$287.5 million, with its two biggest shareholders, including GBS Venture Partners, backing the transaction.